
---
title: '浙江医药：ARX305获得药物临床试验申请受理通知书'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=2821'
author: 证券时报网
comments: false
date: Wed, 22 Dec 2021 17:10:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=2821'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS600216" style="color: #2f67d1;text-decoration: none;" code="600216" target="_blank">浙江医药</a>(600216)12月22日晚间公告，公司在研药物注射用重组人源化抗CD70单抗-AS269偶联物（代号：ARX305）获得药物临床试验申请受理通知书。</p>

                  
</div>
            